Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase (PARP) Inhibitors

Therapeutic drugs that block DNA repair, including poly(ADP-ribose) polymerase (PARP) inhibitors, fail due to lack of tumor-selectivity. When PARP inhibitors and β-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels that refuel NQO1-dependent futile redox dru...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Cell
Main Authors: Huang, Xiumei, Motea, Edward A., Moore, Zachary R., Yao, Jun, Dong, Ying, Chakrabarti, Gaurab, Kilgore, Jessica A., Silvers, Molly A., Patidar, Praveen L., Cholka, Agnieszka, Fattah, Farjana, Cha, Yoonjeong, Anderson, Glenda G., Kusko, Rebecca, Peyton, Michael, Yan, Jingsheng, Xie, Xian-Jin, Sarode, Venetia, Williams, Noelle S., Minna, John D., Beg, Muhammad, Gerber, David E., Bey, Erik A., Boothman, David A.
Format: Artigo
Jezik:Inglês
Izdano: 2016
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161231/
https://ncbi.nlm.nih.gov/pubmed/27960087
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.11.006
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki